M
Masashi Idogawa
Researcher at Sapporo Medical University
Publications - 76
Citations - 2052
Masashi Idogawa is an academic researcher from Sapporo Medical University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 24, co-authored 64 publications receiving 1784 citations.
Papers
More filters
Journal ArticleDOI
Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer.
Kazufumi Honda,Tesshi Yamada,Yasuharu Hayashida,Masashi Idogawa,Satoshi Sato,Fumio Hasegawa,Yoshinori Ino,Masaya Ono,Setsuo Hirohashi +8 more
TL;DR: Actinin-4 actively increases cell motility and promotes lymph node metastasis of colorectal cancer.
Journal ArticleDOI
Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors.
Hironobu Sato,Hiromu Suzuki,Minoru Toyota,Masanori Nojima,Reo Maruyama,Shigeru Sasaki,Hideyasu Takagi,Yohei Sogabe,Yasushi Sasaki,Masashi Idogawa,Tomoko Sonoda,Mitsuru Mori,Kohzoh Imai,Takashi Tokino,Yasuhisa Shinomura +14 more
TL;DR: It is demonstrated that Dickkopfs (Dkks) are frequent targets of epigenetic silencing in gastrointestinal tumors, and that loss of DKKs may facilitate tumorigenesis through beta-catenin/T-cell factor-independent mechanisms.
Journal ArticleDOI
E-Cadherin Regulates the Association between β-Catenin and Actinin-4
Yasuharu Hayashida,Kazufumi Honda,Masashi Idogawa,Yoshinori Ino,Masaya Ono,Akihiko Tsuchida,Tatsuya Aoki,Setsuo Hirohashi,Tesshi Yamada +8 more
TL;DR: The association between β-catenin and actinin-4 and its regulation by E-cadherin may represent a novel molecular link connecting cell adhesion and motility and may be worth considering as a therapeutic approach to cancer invasion and metastasis.
Journal ArticleDOI
CHFR Protein Regulates Mitotic Checkpoint by Targeting PARP-1 Protein for Ubiquitination and Degradation
Lisa Kashima,Masashi Idogawa,Hiroaki Mita,Miki Shitashige,Tesshi Yamada,Kazuhiro Ogi,Hiromu Suzuki,Minoru Toyota,Hiroyoshi Ariga,Yasushi Sasaki,Takashi Tokino +10 more
TL;DR: Poly(ADP-ribose) polymerase 1 (PARP-1) is shown to be a novel CHFR-interacting protein, demonstrating a significant advantage for use of combinational chemotherapy with PARP inhibitors for cancer cells resistant to microtubule inhibitors and supporting the data that the interaction between CHFR and PARP- 1 plays an important role in cell cycle regulation and cancer therapeutic strategies.
Journal ArticleDOI
Poly(ADP-Ribose) Polymerase-1 Is a Component of the Oncogenic T-Cell Factor-4/β-Catenin Complex
TL;DR: The expression patterns and functional properties of PARP-1 were highly suggestive of its participation in early colorectal carcinogenesis, and it was identified as a novel coactivator of the β-catenin/TCF-4 complex.